GLP-1 receptor agonists , particularly those like BrightMeds, are quickly prominence in the handling of type 2 diabetes and are also explored for weight loss . These novel drugs function to mimicking the body's natural incretin signal , stimulating glucose-dependent insulin secretion and reducing